Ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['mmsm', 'cartitude 4', 'cartitude']
after quick trip to #asco2023 catching up on cartitude 4 from the confines of my office.. my takeaways.. only 15% triple class refractory.. no diifference by lot.. second heme cancer and neurotox still an issue.. but otherwise encouraging data for #mmsm. 
Oncologist @MGHCancerCenter, Professor @harvardmed, Myeloma doc, clinical trialist, researcher, mom and wife who cares about #myeloma and social issues.